Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
CC transcript
Seagen Inc. (SGEN) Create: Alert

All | News | Filings
Date FiledTypeDescription
07/28/2022 8-K Quarterly results
04/28/2022 8-K Quarterly results
Docs: "Seagen Reports First Quarter 2022 Financial Results"
02/09/2022 8-K Quarterly results
Docs: "Seagen Reports Fourth Quarter and Full Year 2021 Financial Results"
10/28/2021 8-K Quarterly results
Docs: "Seagen Reports Third Quarter 2021 Financial Results"
07/29/2021 8-K Quarterly results
Docs: "Seagen Reports Second Quarter 2021 Financial Results"
02/11/2021 8-K Quarterly results
10/29/2020 8-K Quarterly results
Docs: "Seagen Reports Third Quarter 2020 Financial Results"
07/31/2020 8-K Quarterly results
04/30/2020 8-K Quarterly results
Docs: "Seattle Genetics Reports First Quarter 2020 Financial Results -ADCETRIS ® Net Sales in U.S. and Canada of $164.1 Million in the First Quarter, an Increase of 22 percent Over the First Quarter of 2019- -PADCEV ™ Net Sales in U.S. Reach $34.5 Million in First Full Quarter of Commercialization- -TUKYSA ™ Approved by FDA for Patients with HER2-Positive Metastatic Breast Cancer Who Have Received One or More Prior Anti-HER2 Regimens in the Metastatic Setting- -Conference Call Today at 4:30 p.m. ET-"
02/06/2020 8-K Quarterly results
Docs: "Seattle Genetics Reports Fourth Quarter and Full Year 2019 Financial Results -ADCETRIS ® Net Sales in U.S. and Canada of $627.7 Million in 2019, Including $166.2 Million in the Fourth Quarter- -PADCEV™ Granted Accelerated Approval by FDA for Patients with Locally Advanced or Metastatic Urothelial Cancer Following Platinum-based Chemotherapy and a PD-1 or PD-L1 Inhibitor; U.S. Commercial Launch Underway- -Tucatinib Applications for Approval Submitted to the FDA and EMA for Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer- -Conference Call Today at 4:30 p.m. ET-"
10/29/2019 8-K Quarterly results
Docs: "Seattle Genetics Reports Third Quarter 2019 Financial Results -Record ADCETRIS ® Net Sales in U.S. and Canada of $167.6 Million in the Third Quarter, an Increase of 32 Percent Over the Third Quarter of 2018- -Enfortumab Vedotin Biologics License Application in Locally Advanced or Metastatic Urothelial Cancer Granted Priority Review by FDA; PDUFA Target Action Date March 15, 2020- -Tucatinib HER2CLIMB Pivotal Trial Met Primary and Both Key Secondary Endpoints; New Drug Application to FDA Planned for the First Quarter of 2020- -Conference Call Today at 4:30 p.m. ET-"
07/16/2019 8-K Quarterly results
Docs: "Seattle Genetics Reports Second Quarter 2019 Financial Results -Record ADCETRIS ® Net Sales in U.S. and Canada of $159.0 Million in the Second Quarter, an Increase of 30 Percent Over the Second Quarter of 2018- -Biologics License Application Submitted to FDA for Enfortumab Vedotin to Treat Advanced or Metastatic Urothelial Cancer Based on Results from the EV-201 Pivotal Trial- -Topline Results from Tucatinib HER2CLIMB Pivotal Trial Expected in 2019- -Conference Call Today at 4:30 p.m. ET-"
04/25/2019 8-K Quarterly results
Docs: "Seattle Genetics Reports First Quarter 2019 Financial Results -ADCETRIS ® Net Sales in U.S. and Canada Were $135.0 Million in the First Quarter, an Increase of 42 Percent Over the First Quarter of 2018 -Positive Topline Results from Pivotal Trial of Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer Support Planned 2019 Submission of Biologics License Application- -Target Enrollment Reached in HER2CLIMB Pivotal Trial of Tucatinib in HER2-Positive Metastatic Breast Cancer; Topline Results Expected in 2019- -Conference Call Today at 4:30 p.m. ET-"
02/07/2019 8-K Quarterly results
10/25/2018 8-K Quarterly results
Docs: "Seattle Genetics Reports Third Quarter 2018 Financial Results -ADCETRIS ® Net Sales in U.S. and Canada of $127.0 Million in the Third Quarter- -Positive Top-line Data from ADCETRIS Phase 3 ECHELON-2 Trial in Frontline PTCL; Supplemental BLA Planned for November 2018; Full Data to be Presented at ASH Annual Meeting- -Top-line Data from Enfortumab Vedotin Pivotal Trial in Metastatic Urothelial Cancer Expected in the First Quarter of 2019- -Conference Call Today at 4:30 p.m. ET-"
07/26/2018 8-K Quarterly results
Docs: "Seattle Genetics Reports Second Quarter 2018 Financial Results -Record ADCETRIS ® Net Sales in U.S. and Canada of $122.4 Million in the Second Quarter- -ADCETRIS ECHELON-2 Top-line Results Expected in Early Fourth Quarter 2018- -Enrollment Completed in Pivotal Trial Cohort of Enfortumab Vedotin in Metastatic Urothelial Cancer; EV Top-line Results Expected in First Half of 2019- -Conference Call Today at 4:30 p.m. ET-"
04/26/2018 8-K Quarterly results
Docs: "FORM 8-K",
"Seattle Genetics Reports First Quarter 2018 Financial Results"
02/06/2018 8-K Quarterly results
Docs: "Seattle Genetics Reports Fourth Quarter and Year 2017 Financial Results"
10/26/2017 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : October 26, 2017 Seattle Genetics, Inc. Delaware 0-32405 91-1874389 21823 30 th Drive SE Bothell, Washington 98021 527-4000 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Exchang...",
"Seattle Genetics Reports Third Quarter 2017 Financial Results"
07/27/2017 8-K Quarterly results
Docs: "Seattle Genetics Reports Second Quarter 2017 Financial Results"
04/27/2017 8-K Form 8-K - Current report
02/09/2017 8-K Form 8-K - Current report
10/27/2016 8-K Form 8-K - Current report
07/26/2016 8-K Form 8-K - Current report
04/28/2016 8-K Form 8-K - Current report
02/09/2016 8-K Form 8-K - Current report
10/29/2015 8-K Quarterly results
Docs: "Seattle Genetics Reports Third Quarter 2015 Financial Results"
07/30/2015 8-K Quarterly results
Docs: "Seattle Genetics Reports Second Quarter 2015 Financial Results"
04/30/2015 8-K Quarterly results
Docs: "Seattle Genetics Reports First Quarter 2015 Financial Results"
02/10/2015 8-K Quarterly results
Docs: "Seattle Genetics Reports Fourth Quarter and Year 2014 Financial Results"
10/30/2014 8-K Quarterly results
Docs: "Seattle Genetics Reports Third Quarter 2014 Financial Results"
07/31/2014 8-K Quarterly results
Docs: "Seattle Genetics Reports Second Quarter 2014 Financial Results"
05/01/2014 8-K Quarterly results
Docs: "Seattle Genetics Reports First Quarter 2014 Financial Results"
02/11/2014 8-K Quarterly results
Docs: "Seattle Genetics Reports Fourth Quarter and Year 2013 Financial Results"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy